Nissay Asset Management Corp Japan Has $42.57 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Nissay Asset Management Corp Japan reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 84,909 shares of the medical research company’s stock after selling 14,506 shares during the period. Nissay Asset Management Corp Japan’s holdings in Thermo Fisher Scientific were worth $42,570,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Legacy Wealth Managment LLC ID grew its position in Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after acquiring an additional 22 shares during the last quarter. Kilter Group LLC bought a new position in Thermo Fisher Scientific in the 2nd quarter valued at $25,000. Allied Private Wealth LLC bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth $26,000. High Note Wealth LLC increased its stake in shares of Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after buying an additional 29 shares in the last quarter. Finally, JPL Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific in the third quarter valued at about $28,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $621.87 on Friday. The firm’s 50 day moving average price is $558.64 and its two-hundred day moving average price is $512.08. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $647.00. The stock has a market cap of $229.94 billion, a PE ratio of 33.45, a PEG ratio of 2.57 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter in the previous year, the company posted $4.28 EPS. The business’s revenue for the quarter was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Insider Activity

In other news, VP Lisa P. Britt sold 11,440 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the transaction, the vice president directly owned 14,784 shares in the company, valued at approximately $9,064,366.08. The trade was a 43.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the completion of the sale, the chief operating officer directly owned 24,651 shares of the company’s stock, valued at approximately $13,927,815. This trade represents a 1.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 73,768 shares of company stock valued at $44,122,820. Insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

TMO has been the topic of a number of research analyst reports. Wolfe Research began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price objective on the stock. Jefferies Financial Group reiterated a “buy” rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Morgan Stanley increased their price target on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Finally, Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $619.41.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.